MaxCyte, Inc. (NASDAQ:MXCT) Given Consensus Recommendation of “Hold” by Analysts

MaxCyte, Inc. (NASDAQ:MXCT) has been assigned an average rating of “Hold” from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $5.50.

Several equities analysts have recently commented on MXCT shares. Wall Street Zen upgraded shares of MaxCyte from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings raised MaxCyte from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, June 24th. Finally, Craig Hallum lowered their target price on MaxCyte from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, March 25th.

Institutional Investors Weigh In On MaxCyte

Several institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets increased its holdings in MaxCyte by 39.5% in the third quarter. BNP Paribas Financial Markets now owns 36,271 shares of the company’s stock worth $57,000 after buying an additional 10,263 shares during the last quarter. Prudential Financial Inc. acquired a new stake in MaxCyte in the second quarter valued at approximately $26,000. State of Wyoming bought a new stake in MaxCyte in the second quarter worth approximately $38,000. American Century Companies Inc. increased its stake in shares of MaxCyte by 10.6% during the 2nd quarter. American Century Companies Inc. now owns 196,686 shares of the company’s stock worth $429,000 after purchasing an additional 18,848 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in shares of MaxCyte by 98.1% during the 4th quarter. SG Americas Securities LLC now owns 49,402 shares of the company’s stock valued at $77,000 after purchasing an additional 24,467 shares in the last quarter. 68.81% of the stock is currently owned by institutional investors and hedge funds.

MaxCyte Price Performance

NASDAQ MXCT opened at $1.22 on Friday. The company has a 50 day simple moving average of $1.08 and a 200-day simple moving average of $1.03. The firm has a market capitalization of $130.15 million, a price-to-earnings ratio of -3.28 and a beta of 1.47. MaxCyte has a 52-week low of $0.64 and a 52-week high of $2.37.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.06. The firm had revenue of $6.22 million for the quarter, compared to the consensus estimate of $7.28 million. MaxCyte had a negative net margin of 121.16% and a negative return on equity of 20.03%. On average, analysts predict that MaxCyte will post -0.29 EPS for the current year.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.